Viskase Companies, Inc. ENZN
4.71 USD 0.00 (+0.00%)
At closeJul 30, 2026, 4:00 PM EDT
4.35 Day range 4.71
0.35 52-week range 0.88
- YTD
- +11,675.00%
- 1 year
- +4,610.00%
News
defenseworld.net Enzon Pharmaceuticals (OTCMKTS:ENZN) Shares Pass Above 200 Day Moving Average – Here’s What Happened Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.10 and…
globenewswire.com Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has completed its previously announced exchange offer…
globenewswire.com Enzon Announces Reverse Stock Split CRANFORD, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that the previously approved 1-for-100 reverse stock split…
globenewswire.com Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer…
globenewswire.com Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer…
globenewswire.com Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer…
globenewswire.com Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer…
globenewswire.com Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock CRANFORD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer…
globenewswire.com Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving…
globenewswire.com Enzon and Viskase Announce Amendment to Merger Agreement Enzon and Viskase stockholders will respectively own 45% and 55% of the combined company Enzon and Viskase stockholders will respectively own 45% and 55% of the combined company
globenewswire.com Enzon and Viskase Enter into Merger Agreement Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the…
investorplace.com 7 Undervalued Biotech Stocks to Buy Before They Boom You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
globenewswire.com Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the…